BARCLAYS
7.9.2022 09:01:53 CEST | Business Wire | Press release
Barclays has appointed Daniel Hanna as Global Head of Sustainable Finance for the Corporate and Investment Bank with the responsibility for creating a market-leading center of excellence for sustainable finance. He will be based in London and joins the Corporate and Investment Bank’s Management Committee.
“The center of excellence will bring together the power of our 'One Barclays' approach to deliver a fuller suite of products, solutions, and expertise to clients as they navigate the transition to a low-carbon economy,” said Paul Compton, Global Head of Corporate and Investment Bank and President, Barclays Bank Plc. “He will partner closely with the Sustainable Capital Markets, Sustainable and Impact Banking, and the Sustainable Product Group teams, as well as with Barclays’ Sustainability and ESG team to ensure connectivity with Barclays’ broader firm-wide efforts.”
“We are focused on the delivery of our climate strategy, including capturing new opportunities to deepen client relationships and create new growth for Barclays’ businesses,” said Sasha Wiggins, Barclays’ Group Head of Public Policy and Corporate Responsibility. “Whilst we are already using our expertise across our Corporate and Investment Bank to help clients manage this period of extraordinary change, Daniel’s appointment gives us a powerful focus to create a real point of difference with clients.”
Mr. Hanna joins Barclays from Standard Chartered, where he was most recently Global Head of Sustainable Finance.
“Barclays was one of the first banks to commit to net zero by 2050 and has a fantastic track record of innovation in green and sustainable finance,” said Mr. Hanna. “As the world deals with the impact of high energy prices and climate change, Barclays has a strong platform to help channel capital to the new technologies, and companies, that can help economies decarbonize and drive sustainable growth.”
The transition to a low carbon economy is today’s defining opportunity for innovation and growth - supporting clients in their efforts to decarbonise and adapt their business models is a strategic priority at Barclays. There is a significant opportunity for Barclays to play a leading role in helping to meet the demand for financing to support the energy transition, channelling investment into new green technologies and low-carbon infrastructure projects. Barclays has already facilitated £74bn of green financing, including landmark projects such as supporting the UK Government to issue their first green bond, which will finance projects such as offshore wind and schemes to decarbonise homes and buildings. To find out more about Barclays’ approach to climate change, please visit our website.
About Barclays
Barclays is a British universal bank. We are diversified by business, by different types of customer and client, and geography. Our businesses include consumer banking and payments operations around the world, as well as a top-tier, full service, global corporate and investment bank, all of which are supported by our service company which provides technology, operations and functional services across the Barclays Group. For further information about Barclays, please visit our website home.barclays.
About Barclays Corporate and Investment Bank
Barclays is a consumer and wholesale bank, supporting individuals and small businesses through our consumer banking services, and larger businesses and institutions through our corporate and investment banking services. Our Corporate and Investment Bank is comprised of the Investment Banking, International Corporate Banking, Global Markets and Research businesses; it provides money managers, financial institutions, governments, supranational organisations and corporate clients with services and advice for their funding, financing, strategic and risk management needs. For further information about Barclays Corporate and Investment Bank, please visit our website www.cib.barclays.
About Barclays Commitment to Address Climate Change
In March 2020, Barclays announced an ambition to be a net zero bank by 2050, becoming one of the first banks to do so. Barclays is working to achieve net zero operations, investing in the continued decarbonisation of our operations, and in the development of a net zero pathway for the emissions from our supply chain. Barclays is also committed to aligning its financing with the goals and timelines of the Paris Agreement and to providing the green and sustainable finance required to transform the economies it serves.
About Barclays’ Sustainable Capital Markets (SCM) Team
Barclays’ Sustainable Capital Markets (SCM) team offers a broad range of ESG capital market product types and delivers across multiple client segments to help clients finance their sustainability journeys and formalise their sustainability commitments.
About Barclays’ Sustainable and Impact Banking (SIB) Team
Barclays’ Sustainable and Impact Banking (SIB) team advises and raises capital for emerging growth companies that are addressing ESG issues, as well as for existing clients navigating their energy transitions.
About Barclays’ Sustainable Product Group (SPG) Team
Barclays’ Sustainable Product Group (SPG) team offers a set of green products based on Barclays Green Finance Framework, including Green Innovation Finance, Green Loans, Green Asset Finance, Green Trade Finance, Green Infrastructure and Project Finance, and Green Deposits.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005147/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom